Fig. 4: Ranking probabilities base on the multiple comparisons on ORR, PFS and OS in the subgroup analysis. | British Journal of Cancer

Fig. 4: Ranking probabilities base on the multiple comparisons on ORR, PFS and OS in the subgroup analysis.

From: Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis

Fig. 4

Ranking probabilities based on the multiple comparisons on ORR (a1), PFS (b1) and OS (c1) in the first-line treated group, ORR (a2), PFS (b2) and OS (c2) in the previously treated group, ORR (a3), PFS (b3) and OS (c3) in the PD-1 inhibitor group, ORR (a4), PFS (b4) and OS (c4) in the PD-L1 inhibitor group, PFS (b5) and OS (c5) in the non-squamous group and PFS (b6) and OS (c6) in the squamous group. ICI immune checkpoint inhibitors, chemo-ICI ICI-combined chemotherapy.

Back to article page